sirolimus — Clinical data readout
Q426
The study, which is supported by a $3.0 million non-dilutive grant from the National Cancer Institute, part of the National Institutes of Health, is expected to read out in Q426.Source filing
BDRX biotech catalysts & pipeline
BIODEXA PHARMACEUTICALS PLC · Data as of 2026-10-25
Upcoming catalysts
sirolimus — Interim data
Early 2027
Based on the current rate of PFS event accrual, the pre-specified futility analysis could take place early next year with database lock potentially occurring around the end of next year, both significantly sooner than originally anticipated".Source filing
MTX240 — Clinical data readout
Late 2027
The Phase 1b/2a trial we are working to initiate is designed to establish a safe and effective dose as well as an efficacy signal before the end of 2027.Source filing
sirolimus — Clinical data readout
Q3 2026
An ongoing double-blind, placebo-controlled Phase 2 IIT of eRapa in NMIBC has enrolled all 166 patients and is expected to read out in the third quarter of 2026.Source filing